Amgen (AMGN) Announces Presentation of Data from Three BLINCYTO Phase 2s at ASH 2015
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO® (blinatumomab) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
